DK1763356T3 - Sammensætning der omfatter et survivinantisenseoligonuckleotid og gemcitabin til behandling af cancer - Google Patents

Sammensætning der omfatter et survivinantisenseoligonuckleotid og gemcitabin til behandling af cancer

Info

Publication number
DK1763356T3
DK1763356T3 DK05738307T DK05738307T DK1763356T3 DK 1763356 T3 DK1763356 T3 DK 1763356T3 DK 05738307 T DK05738307 T DK 05738307T DK 05738307 T DK05738307 T DK 05738307T DK 1763356 T3 DK1763356 T3 DK 1763356T3
Authority
DK
Denmark
Prior art keywords
cancer
oligonucleotide
survivinantisense
gemcitabine
treatment
Prior art date
Application number
DK05738307T
Other languages
Danish (da)
English (en)
Inventor
Bharvin Kumar Patel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1763356T3 publication Critical patent/DK1763356T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05738307T 2004-04-22 2005-04-15 Sammensætning der omfatter et survivinantisenseoligonuckleotid og gemcitabin til behandling af cancer DK1763356T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56454004P 2004-04-22 2004-04-22
PCT/US2005/012968 WO2005107771A2 (fr) 2004-04-22 2005-04-15 Cancerotherapie combinatoire

Publications (1)

Publication Number Publication Date
DK1763356T3 true DK1763356T3 (da) 2008-10-13

Family

ID=35094133

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05738307T DK1763356T3 (da) 2004-04-22 2005-04-15 Sammensætning der omfatter et survivinantisenseoligonuckleotid og gemcitabin til behandling af cancer
DK07119706.5T DK1913947T3 (da) 2004-04-22 2005-04-15 Kombinationsterapi til behandling af kræft

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07119706.5T DK1913947T3 (da) 2004-04-22 2005-04-15 Kombinationsterapi til behandling af kræft

Country Status (17)

Country Link
US (3) US20070244065A1 (fr)
EP (3) EP1763356B1 (fr)
JP (1) JP2007533742A (fr)
CN (2) CN101683355A (fr)
AT (2) ATE401088T1 (fr)
AU (1) AU2005240020B2 (fr)
BR (1) BRPI0509927A (fr)
CA (1) CA2562750A1 (fr)
CY (2) CY1110440T1 (fr)
DE (1) DE602005008241D1 (fr)
DK (2) DK1763356T3 (fr)
ES (2) ES2308488T3 (fr)
MX (1) MXPA06012132A (fr)
PL (2) PL1763356T3 (fr)
PT (2) PT1913947E (fr)
SI (2) SI1913947T1 (fr)
WO (1) WO2005107771A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2310006A4 (fr) * 2008-07-03 2012-04-25 Mayo Foundation Traitement du cancer
FR2955112B1 (fr) 2010-01-14 2012-01-20 Isp Investments Inc Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant
WO2012058462A2 (fr) * 2010-10-29 2012-05-03 Isis Pharmaceuticals, Inc. Polythérapie destinée au traitement du cancer
AU2012253571A1 (en) 2011-05-09 2014-01-09 Mayo Foundation For Medical Education And Research Cancer treatments
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
EP3154586B1 (fr) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Traitement de lymphomes
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (fr) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Procédés de traitement du cancer par interféron
WO2017139698A1 (fr) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Traitements des cancers hématologiques
EP3432928A4 (fr) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Procédés d'amélioration de l'indice thérapeutique d'un médicament chimiothérapeutique
EP3432926A4 (fr) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Procédés de réduction de la toxicité d'un médicament chimiothérapeutique
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2018045239A1 (fr) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Compositions d'agents de liaison et de porteuses pd-l1 pour le traitement de cancers
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｔ細胞癌を標的とする為の方法及び組成物
KR20230011473A (ko) 2016-09-06 2023-01-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｐｄ－ｌ１ 발현 암의 치료 방법
EP3509635A1 (fr) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Méthodes de traitement d'un cancer du sein triple-négatif à l'aide de compositions d'anticorps et de protéines porteuses
RU2021128415A (ru) 2016-09-06 2021-11-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
IL291917A (en) * 2019-10-02 2022-06-01 Sirnaomics Inc Oligonucleotides with nucleoside analogs, compositions comprising same and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184365B1 (fr) * 1984-12-04 1993-08-04 Eli Lilly And Company Traitement de tumeurs chez les mammifères
US6077709A (en) * 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
DK1592793T3 (da) * 2003-02-10 2009-10-26 Santaris Pharma As Oligomeriske forbindelser for modulation af Survivin ekspression

Also Published As

Publication number Publication date
US20070244065A1 (en) 2007-10-18
PL1763356T3 (pl) 2008-12-31
AU2005240020B2 (en) 2011-02-10
PL1913947T3 (pl) 2012-05-31
ES2308488T3 (es) 2008-12-01
EP1763356B1 (fr) 2008-07-16
EP1763356A2 (fr) 2007-03-21
EP1913947A1 (fr) 2008-04-23
CN101683355A (zh) 2010-03-31
WO2005107771A3 (fr) 2006-06-08
AU2005240020A1 (en) 2005-11-17
DK1913947T3 (da) 2012-02-06
SI1913947T1 (sl) 2012-02-29
US20090247611A1 (en) 2009-10-01
PT1913947E (pt) 2012-01-19
US20120022140A1 (en) 2012-01-26
PT1763356E (pt) 2008-09-05
ES2376484T3 (es) 2012-03-14
DE602005008241D1 (de) 2008-08-28
WO2005107771A2 (fr) 2005-11-17
CN1950094A (zh) 2007-04-18
JP2007533742A (ja) 2007-11-22
EP1913947B1 (fr) 2011-12-28
CA2562750A1 (fr) 2005-11-17
MXPA06012132A (es) 2007-01-17
CY1110440T1 (el) 2015-04-29
SI1763356T1 (sl) 2008-12-31
BRPI0509927A (pt) 2007-09-25
ATE401088T1 (de) 2008-08-15
ATE538800T1 (de) 2012-01-15
EP2145626A1 (fr) 2010-01-20
CY1112397T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
DK1763356T3 (da) Sammensætning der omfatter et survivinantisenseoligonuckleotid og gemcitabin til behandling af cancer
DK1853250T3 (da) Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
UA108832C2 (uk) Комбінації кон'югата анти-her2-антитіло-лікарський засіб і хіміотерапевтичних засобів і способи застосування
BRPI0511139B8 (pt) compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
PH12012502380B1 (en) Methods of treatment of pancreatic cancer
DK2201840T3 (da) Hæmmere af Brutons tyrosinkinase
NO20065368L (no) Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin
DK1846406T3 (da) Maleimidderivater, farmaceutiske sammensætninger og fremgangsmåder til behandling af cancer
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
IN2012DN02018A (fr)
DK1505990T3 (da) Fremgangsmåder til behandling af hepatitis
WO2008137867A3 (fr) Compositions comportant des agents thérapeutiques mir34 pour traiter le cancer
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
ATE499098T1 (de) Verwendung von parp-1-hemmern
WO2007123511A3 (fr) Schémas posologiques pour le traitement du cancer
DK1848440T3 (da) Farmaceutisk sammensætning og fremgangsmåde til regenerering af myofibre i behandlingen af muskelskader
ATE477820T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
TW200509925A (en) Method comprising irinotecan for treatment of breast cancer
DK1962822T3 (da) Terapi af maligne neoplasier
UA110795C2 (uk) Спосіб лікування раку підшлункової залози
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
DK2026832T3 (da) Kombination af interferon-beta og et cladribin-regime til behandling af multipel sklerose
UA96339C2 (ru) Гептациклические соединения и их фармацевтическое применение для профилактики и лечения диабета и метаболического синдрома